RU2014141984A - Способы и композиции для лечения воспаления - Google Patents
Способы и композиции для лечения воспаления Download PDFInfo
- Publication number
- RU2014141984A RU2014141984A RU2014141984A RU2014141984A RU2014141984A RU 2014141984 A RU2014141984 A RU 2014141984A RU 2014141984 A RU2014141984 A RU 2014141984A RU 2014141984 A RU2014141984 A RU 2014141984A RU 2014141984 A RU2014141984 A RU 2014141984A
- Authority
- RU
- Russia
- Prior art keywords
- nanoparticle
- antigen
- complex
- hch
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 4
- 238000000034 method Methods 0.000 title claims 5
- 206010061218 Inflammation Diseases 0.000 title claims 3
- 230000004054 inflammatory process Effects 0.000 title claims 3
- 239000002105 nanoparticle Substances 0.000 claims abstract 51
- 239000000427 antigen Substances 0.000 claims abstract 14
- 102000036639 antigens Human genes 0.000 claims abstract 14
- 108091007433 antigens Proteins 0.000 claims abstract 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 9
- 241000606125 Bacteroides Species 0.000 claims abstract 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract 6
- 244000005700 microbiome Species 0.000 claims abstract 4
- 230000002496 gastric effect Effects 0.000 claims abstract 3
- 241000186000 Bifidobacterium Species 0.000 claims abstract 2
- 241000193403 Clostridium Species 0.000 claims abstract 2
- 241000186394 Eubacterium Species 0.000 claims abstract 2
- 241000605909 Fusobacterium Species 0.000 claims abstract 2
- 108010061711 Gliadin Proteins 0.000 claims abstract 2
- 102100034343 Integrase Human genes 0.000 claims abstract 2
- 108010061833 Integrases Proteins 0.000 claims abstract 2
- 229920000057 Mannan Polymers 0.000 claims abstract 2
- 108010058846 Ovalbumin Proteins 0.000 claims abstract 2
- 241000206591 Peptococcus Species 0.000 claims abstract 2
- 241000191992 Peptostreptococcus Species 0.000 claims abstract 2
- 241000192031 Ruminococcus Species 0.000 claims abstract 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 239000002502 liposome Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 229940092253 ovalbumin Drugs 0.000 claims abstract 2
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 230000031990 negative regulation of inflammatory response Effects 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 230000009285 allergic inflammation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Наночастица, содержащая комплекс антиген-ГКГС, где а) комплекс содержит белок ГКГС, находящийся в комплексе с антигеном, полученным из микроорганизма желудочно-кишечного тракта, или с ЖКТ-ассоциированным антигеном;.b) диаметр наночастицы выбран из группы: приблизительно от 1 нм приблизительно до 100 нм; приблизительно от 5 нм приблизительно до 50 нм или приблизительно от 5 приблизительно до 15 нмc) соотношение комплексов антиген-ГКГС и наночастиц составляет приблизительно от 10:1 приблизительно до 1000:1d) комплекс антиген-ГКГС связан с наночастицей при помощи ковалентной или нековалентной связи.2. Наночастица по п. 1, где комплекс антиген-ГКГС ковалентно связан с наночастицей посредством линкера размером менее 5 кДа.3. Наночастица по п. 1, где антиген получен из микроорганизма, выбранного из группы, состоящей из: Bacteroides Clostridium, Fusobacterium, Eubacterium, Ruminococcus, Peptococcus, Peptostreptococcus или Bifidobacterium, или представляет собой ЖКТ-ассоциированный антиген, полученный из белка, выбранного из группы, состоящей из: овальбумина, маннана дрожжей или глиадина.4. Наночастица по п. 1, где антиген получен из Bacteroides или из белка Bacteroides.5. Наночастица по п. 1, где антиген получен из интегразы Bacteroides.6. Наночастица по п. 1, где антиген содержит пептид, последовательность которого идентична по меньшей мере на 80% пептидной последовательности, выбранной из группы SEQ ID Nos. 1, 4, 5, 6, 7 или 8.7. Наночастица по п. 1, где наночастица является биосовместимой или биоабсорбируемой.8. Наночастица по п. 1, где ГКГС включает ГКГС класса I или ГКГС класса II.9. Наночастица по п. 1, где наночастица не является липосомой.10. Композиция, содержащая наночастицу по любому из пп. 1-9 и носитель.11. Способ изготовления или получения наночастицы по любому из пп. 1-9, включающий образование комплекса между комплексом антиген-ГКГС и наночастиц
Claims (25)
1. Наночастица, содержащая комплекс антиген-ГКГС, где а) комплекс содержит белок ГКГС, находящийся в комплексе с антигеном, полученным из микроорганизма желудочно-кишечного тракта, или с ЖКТ-ассоциированным антигеном;.
b) диаметр наночастицы выбран из группы: приблизительно от 1 нм приблизительно до 100 нм; приблизительно от 5 нм приблизительно до 50 нм или приблизительно от 5 приблизительно до 15 нм
c) соотношение комплексов антиген-ГКГС и наночастиц составляет приблизительно от 10:1 приблизительно до 1000:1
d) комплекс антиген-ГКГС связан с наночастицей при помощи ковалентной или нековалентной связи.
2. Наночастица по п. 1, где комплекс антиген-ГКГС ковалентно связан с наночастицей посредством линкера размером менее 5 кДа.
3. Наночастица по п. 1, где антиген получен из микроорганизма, выбранного из группы, состоящей из: Bacteroides Clostridium, Fusobacterium, Eubacterium, Ruminococcus, Peptococcus, Peptostreptococcus или Bifidobacterium, или представляет собой ЖКТ-ассоциированный антиген, полученный из белка, выбранного из группы, состоящей из: овальбумина, маннана дрожжей или глиадина.
4. Наночастица по п. 1, где антиген получен из Bacteroides или из белка Bacteroides.
5. Наночастица по п. 1, где антиген получен из интегразы Bacteroides.
6. Наночастица по п. 1, где антиген содержит пептид, последовательность которого идентична по меньшей мере на 80% пептидной последовательности, выбранной из группы SEQ ID Nos. 1, 4, 5, 6, 7 или 8.
7. Наночастица по п. 1, где наночастица является биосовместимой или биоабсорбируемой.
8. Наночастица по п. 1, где ГКГС включает ГКГС класса I или ГКГС класса II.
9. Наночастица по п. 1, где наночастица не является липосомой.
10. Композиция, содержащая наночастицу по любому из пп. 1-9 и носитель.
11. Способ изготовления или получения наночастицы по любому из пп. 1-9, включающий образование комплекса между комплексом антиген-ГКГС и наночастицей.
12. Выделенный или очищенный полипептид, содержащий аминокислотную последовательность, выбранную из группы SEQ ID Nos. 1, 4, 5, 6, 7 или 8, или полипептид, последовательность которого идентична по меньшей мере на 80% последовательности SEQ ID Nos. 1, 4, 5, 6, 7 или 8, или полипептид, кодируемый полинуклеотидом, гибридизующимся в условиях от умеренной до высокой жесткости с полинуклеотидом, кодирующим последовательность SEQ ID Nos. 1, 4, 5, 6, 7 или 8 или последовательность, идентичную по меньшей мере на 80% последовательности SEQ ID Nos. 1, 4, 5, 6, 7 или 8, или комплементарным ему полинуклеотидом.
13. Выделенный и очищенный полинуклеотид, кодирующий полипептид по п. 12 или его эквивалент, или полнуклеотид, гибридизующийся в жестких условиях с полинуклеотидом, его эквивалентом или комплементарным ему полинуклеотидом, где жесткие условия включают инкубацию при температурах приблизительно от 25°С приблизительно до 37°С, концентрацию буфера для гибридизации приблизительно от 6х SSC приблизительно до 10х SSC, концентрацию формамида приблизительно от 0% приблизительно до 25% и отмывочного раствора приблизительно от 4х SSC приблизительно до 8х SSC.
14. Композиция, содержащая: а) полипептид по п. 12 или полинуклеотид по п. 13 и b) носитель.
15. Наночастица по любому из пп. 1-9 для применения в способе индукции противовоспалительного ответа в клетке или ткани, включающий приведение клетки или ткани в контакт с наночастицами в эффективном количестве.
16. Наночастица по любому из пп. 1-9 для применения в способе лечения воспаления у нуждающегося в этом пациента, включающий введение пациенту комплекса наночастиц в эффективном количестве.
17. Наночастица по любому из пп. 1-9 для применения в способе аккумуляции противовоспалительных Т клеток и/или противовоспалительных клеток в желудочно-кишечном тракте нуждающегося в этом пациента, включающий введение пациенту наночастиц в эффективном количестве.
18. Наночастица по п. 16 или 17, где пациент страдает желудочно-кишечным заболеванием, выбранным из группы, состоящей из: воспалительного заболевания кишечника, колита, болезни Крона, аллергического воспаления желудочно-кишечного тракта или целиакии.
19. Наночастица по п. 15, где клетка или ткань представляет собой клетку или ткань желудочно-кишечного тракта.
20. Наночастица по п. 17, где Т клетка представляет собой CD4+ Т клетку или CD8+ Т клетку.
21. Наночастица по п. 17, где Т клетка секретирует IL-10 или TGFβ.
22. Наночастица по п. 15 или 19, где противовоспалительный ответ индуцируют в желудочно-кишечном тракте.
23. Наночастица по п. 16, где осуществляют лечение воспаления желудочно-кишечного тракта.
24. Наночастица по любому из пп. 1-9 для применения в способе переноса цитотоксических Т-лимфоцитов, направленных против эпитопов бактерий кишечника, у нуждающегося в этом пациента, включающий введение пациенту комплексов антиген-ГКГС-наночастица в эффективном количестве.
25. Наночастица по п. 24, где цитотоксические Т-лимфоциты распознают эпитоп бактерий кишечника с низкой авидностью.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615743P | 2012-03-26 | 2012-03-26 | |
| US61/615,743 | 2012-03-26 | ||
| PCT/IB2013/052352 WO2013144811A2 (en) | 2012-03-26 | 2013-03-25 | Methods and compositions for treating inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014141984A true RU2014141984A (ru) | 2016-05-20 |
| RU2689563C2 RU2689563C2 (ru) | 2019-05-28 |
Family
ID=48444453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014141984A RU2689563C2 (ru) | 2012-03-26 | 2013-03-25 | Композиция антиген-гкгс-наночастиц для индуцирования противовоспалительного ответа в кишечнике и способ ее получения |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10988516B2 (ru) |
| EP (2) | EP2830654B8 (ru) |
| JP (3) | JP6199955B2 (ru) |
| CN (2) | CN110354278B (ru) |
| AU (2) | AU2013202911A1 (ru) |
| CA (1) | CA2868551C (ru) |
| DK (1) | DK2830654T3 (ru) |
| ES (1) | ES2744491T3 (ru) |
| HK (1) | HK1206641A1 (ru) |
| IL (2) | IL234829B (ru) |
| MX (1) | MX363000B (ru) |
| PL (1) | PL2830654T3 (ru) |
| PT (1) | PT2830654T (ru) |
| RU (1) | RU2689563C2 (ru) |
| WO (1) | WO2013144811A2 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| WO2015063616A2 (en) | 2013-11-04 | 2015-05-07 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| HUE037476T2 (hu) * | 2014-12-23 | 2018-08-28 | 4D Pharma Res Ltd | Pirin polipeptid és immunmodulálás |
| AU2016275312B2 (en) * | 2015-05-06 | 2021-12-23 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| CN117815381A (zh) * | 2015-05-27 | 2024-04-05 | 西北大学 | 用于调节免疫反应的碳水化合物修饰的粒子和粒子制剂 |
| KR102489353B1 (ko) | 2015-06-01 | 2023-01-17 | 캘리포니아 인스티튜트 오브 테크놀로지 | 특정 집단에 대한 항원으로 t 세포를 스크리닝하기 위한 조성물 및 방법 |
| EP3716949A4 (en) * | 2017-11-29 | 2022-05-18 | UTI Limited Partnership | METHODS OF TREATING AN AUTOIMMUNE DISEASE |
| BE1026147B1 (nl) * | 2018-03-29 | 2019-10-28 | Farm@Nutrition Besloten Vennootschap Met Beperkte Aansprakelijkheid | Samenstelling voor een voedingsadditief voor dieren en werkwijze om het additief toe te dienen. |
| CN116790402B (zh) * | 2023-01-14 | 2024-05-14 | 西北农林科技大学 | 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用 |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4367110A (en) | 1979-07-02 | 1983-01-04 | Toppan Printing Co. | Decorative laminate and a manufacturing method therefor |
| US4452901A (en) | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4478946A (en) | 1981-07-02 | 1984-10-23 | South African Inventions Development Corporation | Carrier bound immunosorbent |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| EP0092227B1 (en) | 1982-04-19 | 1988-07-27 | Nissan Motor Co., Ltd. | Method for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| ATE66469T1 (de) | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
| US5171582A (en) | 1985-07-31 | 1992-12-15 | Ghent William R | Treatment of iodine deficiency diseases |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US6106840A (en) | 1988-06-23 | 2000-08-22 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| US5260422A (en) | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| US4859839A (en) | 1988-07-08 | 1989-08-22 | Counter Computer Corporation | Point-of-sale terminal for laundry or dry cleaning establishments |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| EP0630255B1 (en) | 1991-04-23 | 2002-12-18 | Anergen, Inc. | Mhc conjugates useful in ameliorating autoimmunity |
| US5200189A (en) | 1991-07-23 | 1993-04-06 | Ecolab Inc. | Peroxyacid antimicrobial composition |
| EP0627934A4 (en) | 1992-02-27 | 1997-01-08 | Univ Leland Stanford Junior | EARLY ANTIGEN FOR AUTOIMMUNE DIABETE. |
| JP2631436B2 (ja) | 1992-07-24 | 1997-07-16 | 徳厚 小島 | 排水立て管継手 |
| US5972336A (en) | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
| CA2185810A1 (en) | 1994-03-28 | 1995-10-05 | Jo Klaveness | Liposomes |
| US6103379A (en) | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| DE19508058A1 (de) | 1995-02-21 | 1996-08-22 | Schering Ag | Verfahren zur Herstellung von DTPA-Tetraestern der terminalen Carbonsäuren und deren Verwendung zur Herstellung pharmazeutischer Mittel |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6033864A (en) * | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| US20050003431A1 (en) | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| ES2221065T3 (es) | 1996-08-16 | 2004-12-16 | The President And Fellows Of Harvard College | Proteinas de fusion de clase ii del mhc, solubles, monovalentes o polivalentes, y sus usos. |
| DK1017721T3 (da) | 1997-09-16 | 2009-04-20 | Univ Oregon Health & Science | Rekombinante MHC molekyler, der kan anvendes til manipulation af antigenspecifikke T-celler |
| CA2321262A1 (en) | 1998-02-19 | 1999-08-26 | President And Fellows Of Harvard College | Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor |
| EP1094828A4 (en) | 1998-05-07 | 2005-01-26 | Univ California | USE OF TARGETED, NEGLIGATED TISSUE ANTIGENS TO MODULATE IMMUNE REACTIONS |
| DE19825371A1 (de) | 1998-06-06 | 1999-12-09 | Bayer Ag | Elektrochrome Anzeigevorrichtung mit isolierten Zuleitungen |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| US7807377B2 (en) | 1998-10-20 | 2010-10-05 | Salvatore Albani | Method of isolating antigen-specific T cells employing artificial antigen presenting cells |
| US6150022A (en) | 1998-12-07 | 2000-11-21 | Flex Products, Inc. | Bright metal flake based pigments |
| JP2000213425A (ja) | 1999-01-20 | 2000-08-02 | Hino Motors Ltd | Ｅｇｒク―ラ |
| US7090973B1 (en) * | 1999-04-09 | 2006-08-15 | Oscient Pharmaceuticals Corporation | Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics |
| HUP0201222A3 (en) | 1999-05-06 | 2004-07-28 | Genetics Inst Llc Delaware All | Use of soluble constimulatory molecules to enhance immune responses |
| JP2003510341A (ja) | 1999-10-06 | 2003-03-18 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 細胞ターゲッティング組成物及びそれらを使用する方法 |
| US6585947B1 (en) | 1999-10-22 | 2003-07-01 | The Board Of Trustess Of The University Of Illinois | Method for producing silicon nanoparticles |
| US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| KR100379250B1 (ko) | 2000-12-04 | 2003-04-08 | 한국과학기술연구원 | 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법 |
| CA2440474A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| DE10117858A1 (de) | 2001-04-10 | 2002-10-24 | Gsf Forschungszentrum Umwelt | MHC-Tetramere |
| WO2009003492A1 (en) | 2007-07-03 | 2009-01-08 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
| CA2449990A1 (en) | 2001-06-22 | 2003-01-03 | The University Of British Columbia | Type 1 diabetes diagnostics and therapeutics |
| US20070129307A1 (en) | 2001-06-22 | 2007-06-07 | The University Of British Columbia | Insulin epitopes for the treatment of type 1 diabetes |
| US20030124149A1 (en) | 2001-07-06 | 2003-07-03 | Shalaby Shalaby W. | Bioactive absorbable microparticles as therapeutic vaccines |
| ATE388691T1 (de) | 2001-07-10 | 2008-03-15 | Univ North Carolina State | Träger zur freisetzung von nanopartikeln |
| DE10144252A1 (de) | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
| ES2405405T3 (es) * | 2001-12-17 | 2013-05-31 | Corixa Corporation | Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino |
| US6688494B2 (en) | 2001-12-20 | 2004-02-10 | Cima Nanotech, Inc. | Process for the manufacture of metal nanoparticle |
| US7285289B2 (en) | 2002-04-12 | 2007-10-23 | Nagy Jon O | Nanoparticle vaccines |
| AU2003256506B2 (en) | 2002-07-12 | 2009-06-04 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
| DE10310261A1 (de) | 2003-03-05 | 2004-09-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Identifizierung von Antigen-Epitopen |
| US20040197304A1 (en) | 2003-04-01 | 2004-10-07 | The Procter & Gamble Company And Alimentary Health, Ltd. | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
| US6929675B1 (en) | 2003-04-24 | 2005-08-16 | Sandia Corporation | Synthesis metal nanoparticle |
| US20050118102A1 (en) | 2003-04-28 | 2005-06-02 | Intematix Corporation | Spin resonance heating and/or imaging in medical applications |
| DK1623017T3 (da) | 2003-05-08 | 2011-01-10 | Life Technologies Corp | Frembringelse og isolering af antigenspecifikke T-celler |
| US8758767B2 (en) | 2003-05-20 | 2014-06-24 | Albert Einstein College Of Medicine Of Yeshiva University | Antigens targeted by prevalent pathogennic T cells in type 1 diabetes and uses thereof |
| US7060121B2 (en) | 2003-06-25 | 2006-06-13 | Hsing Kuang Lin | Method of producing gold nanoparticle |
| US7812116B2 (en) | 2003-07-03 | 2010-10-12 | Rush University Medical Center | Immunogenic peptides |
| US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
| GB0321937D0 (en) | 2003-09-19 | 2003-10-22 | Univ Liverpool | Nanoparticle conjugates and method of production thereof |
| EP1671055B1 (en) | 2003-10-09 | 2013-03-20 | Brooks Instrument LLC | Valve assembly |
| DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| CA2571899A1 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| US9079765B2 (en) | 2004-10-01 | 2015-07-14 | Midatech Ltd. | Nanoparticles comprising antigens and adjuvants, and immunogenic structures |
| WO2006054806A1 (ja) | 2004-11-22 | 2006-05-26 | Locomogene, Inc. | クローン病関連自己抗原 |
| US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
| US20070059775A1 (en) | 2005-03-29 | 2007-03-15 | The Trustees Of Columbia University In The City Of New York | Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and MR imaging techniques |
| US7562421B2 (en) | 2005-04-03 | 2009-07-21 | Magen Eco Energy A.C.S. Ltd. | Connecting clasp |
| US7326399B2 (en) | 2005-04-15 | 2008-02-05 | Headwaters Technology Innovation, Llc | Titanium dioxide nanoparticles and nanoparticle suspensions and methods of making the same |
| CN101247826A (zh) | 2005-08-25 | 2008-08-20 | 大鹏药品工业株式会社 | 固定或内包t细胞识别抗原表位肽的生物降解性纳米粒子 |
| CA2631714C (en) | 2005-12-02 | 2014-09-16 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| US20100061984A1 (en) | 2006-01-20 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| PL2059256T3 (pl) | 2006-08-11 | 2017-02-28 | Life Sciences Research Partners Vzw | Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych |
| US7816814B1 (en) | 2006-08-18 | 2010-10-19 | Hennessy Michael J | Bi-directional power converters |
| US20100056444A1 (en) | 2006-10-12 | 2010-03-04 | Sven Martin Jacobson | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| MX2009007101A (es) | 2006-12-29 | 2009-12-01 | Univ Washington | Superficies y materiales antibioincrustación bifuncionales. |
| WO2008115641A2 (en) | 2007-02-15 | 2008-09-25 | Yale University | Modular nanoparticles for adaptable vaccines |
| JP5650406B2 (ja) | 2007-03-07 | 2015-01-07 | ユーティーアイ リミテッド パートナーシップ | 自己免疫状態の予防および治療のための組成物および方法 |
| US20150250871A1 (en) | 2007-03-07 | 2015-09-10 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| US20140105980A1 (en) | 2012-10-11 | 2014-04-17 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| US20100151031A1 (en) | 2007-03-23 | 2010-06-17 | Desimone Joseph M | Discrete size and shape specific organic nanoparticles designed to elicit an immune response |
| WO2009013741A2 (en) | 2007-07-22 | 2009-01-29 | Camtek Ltd | Method and system for controlling a manufacturing process |
| JP5085240B2 (ja) | 2007-09-03 | 2012-11-28 | 日本電波工業株式会社 | 水晶デバイス及び水晶デバイスの製造方法 |
| EP2399610A3 (en) | 2007-09-24 | 2012-09-05 | Bar-Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| WO2009064273A1 (en) | 2007-11-16 | 2009-05-22 | Paul Appelbaum | Apparatus and method for packaging articles in clear plastic packages |
| US8779088B2 (en) * | 2007-12-17 | 2014-07-15 | Marfl Ab | Vaccine for the treatment of Mycobacterium related disorders |
| US8629098B2 (en) | 2008-01-15 | 2014-01-14 | Yale University | Compositions and methods for adoptive and active immunotherapy |
| US20110165647A1 (en) | 2008-02-04 | 2011-07-07 | Fernig David G | Nanoparticle conjugates |
| JP2011525477A (ja) | 2008-03-04 | 2011-09-22 | リクイディア・テクノロジーズ・インコーポレーテッド | 免疫調節剤粒子および処置方法 |
| WO2009126835A2 (en) | 2008-04-09 | 2009-10-15 | University Of Washington Techtransfer Invention Licensing | Magnetic nanoparticle and method for imaging t cells |
| US20090258355A1 (en) | 2008-04-11 | 2009-10-15 | Brookhaven Science Associates, Llc | Nanoscale Clusters and Methods of Making Same |
| EP2324055A2 (en) | 2008-08-25 | 2011-05-25 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| WO2010037397A1 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| CA2642141A1 (en) | 2008-10-20 | 2010-04-20 | Innovative Microelectronics Inc. | Flange alignment pin |
| US9267945B2 (en) | 2008-11-12 | 2016-02-23 | Yeda Research And Development Co. Ltd. | Diagnosis of multiple sclerosis |
| WO2010080032A2 (en) | 2009-01-09 | 2010-07-15 | Stichting Het Nederlands Kanker Instituut | Bead-assisted viral transduction |
| AU2010206854A1 (en) | 2009-01-20 | 2011-08-04 | Myelin Repair Foundation, Inc. | Compositions and methods for induction of antigen-specific tolerance |
| US8383085B2 (en) | 2009-05-29 | 2013-02-26 | University Of Manitoba | Methods of making iron-containing nanoparticles |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| GB0922066D0 (en) | 2009-12-17 | 2010-02-03 | Univ Belfast | Modulator |
| GB201003088D0 (en) | 2010-02-24 | 2010-04-14 | Univ Exeter | Method for the preparation of a novel nanoparticle conjugate |
| SG187201A1 (en) | 2010-07-26 | 2013-02-28 | Qu Biolog Inc | Immunogenic anti-inflammatory compositions |
| EP2640711B1 (en) | 2010-08-25 | 2015-10-14 | Davuluri, Ramamohan Rao | Improved process for the preparation of rufinamide |
| JP6027969B2 (ja) | 2010-09-03 | 2016-11-16 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 共有結合性ペプチドを有する組み換え型ｔ細胞受容体リガンド |
| AU2011310513C1 (en) | 2010-09-29 | 2016-06-02 | Uti Limited Partnership | Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| CN103917249B (zh) | 2011-09-07 | 2016-11-09 | Mida科技有限公司 | 纳米颗粒‑肽组合物 |
| WO2013043662A1 (en) | 2011-09-22 | 2013-03-28 | Marv Enterprises Llc | Method for the treatment of multiple sclerosis |
| EP2591801A1 (en) | 2011-11-14 | 2013-05-15 | Universitätsklinikum Hamburg-Eppendorf | Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
| US20130128138A1 (en) | 2011-11-18 | 2013-05-23 | Shenzhen China Star Optoelectronics Technolog Co., LTD. | Flat Panel Display Device, Stereoscopic Display Device, Plasma Display Device |
| JP2015500296A (ja) | 2011-12-09 | 2015-01-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 定義された動的形状を有する人工抗原提示細胞 |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US20150150996A1 (en) | 2012-06-06 | 2015-06-04 | Northwestern University | Compositions and methods for antigen-specific tolerance |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| SG11201504414UA (en) | 2012-12-21 | 2015-07-30 | Hoffmann La Roche | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
| US9335768B2 (en) | 2013-09-12 | 2016-05-10 | Lam Research Corporation | Cluster mass flow devices and multi-line mass flow devices incorporating the same |
| WO2015063616A2 (en) | 2013-11-04 | 2015-05-07 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
| WO2015200728A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| WO2016145605A1 (zh) | 2015-03-17 | 2016-09-22 | 王忠堂 | 一种便携式智能超声多普勒动态实时监测装置 |
| AU2016275312B2 (en) | 2015-05-06 | 2021-12-23 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| BR112019009477A2 (pt) | 2016-11-09 | 2019-07-30 | Uti Lp | moléculas de classe ii de pmhc recombinantes |
| BR112019021022A2 (pt) | 2017-04-07 | 2020-06-09 | Uti Lp | ensaio para medir a potência de interações receptor-ligante em nanomedicamentos |
| EP3716949A4 (en) | 2017-11-29 | 2022-05-18 | UTI Limited Partnership | METHODS OF TREATING AN AUTOIMMUNE DISEASE |
-
2013
- 2013-03-15 US US13/842,302 patent/US10988516B2/en active Active
- 2013-03-25 PT PT13722836T patent/PT2830654T/pt unknown
- 2013-03-25 WO PCT/IB2013/052352 patent/WO2013144811A2/en active Application Filing
- 2013-03-25 MX MX2014011623A patent/MX363000B/es unknown
- 2013-03-25 ES ES13722836T patent/ES2744491T3/es active Active
- 2013-03-25 AU AU2013202911A patent/AU2013202911A1/en not_active Abandoned
- 2013-03-25 EP EP13722836.7A patent/EP2830654B8/en active Active
- 2013-03-25 RU RU2014141984A patent/RU2689563C2/ru active
- 2013-03-25 CN CN201910811575.4A patent/CN110354278B/zh active Active
- 2013-03-25 DK DK13722836.7T patent/DK2830654T3/da active
- 2013-03-25 JP JP2015502510A patent/JP6199955B2/ja active Active
- 2013-03-25 CN CN201380022126.2A patent/CN104321077A/zh active Pending
- 2013-03-25 PL PL13722836T patent/PL2830654T3/pl unknown
- 2013-03-25 EP EP19175655.0A patent/EP3590531A1/en active Pending
- 2013-03-25 CA CA2868551A patent/CA2868551C/en active Active
-
2014
- 2014-09-23 IL IL234829A patent/IL234829B/en active IP Right Grant
-
2015
- 2015-08-03 HK HK15107409.3A patent/HK1206641A1/xx unknown
-
2016
- 2016-05-18 AU AU2016203231A patent/AU2016203231B2/en active Active
-
2017
- 2017-08-24 JP JP2017160799A patent/JP6570082B2/ja active Active
-
2019
- 2019-04-10 JP JP2019074507A patent/JP2019108399A/ja active Pending
- 2019-09-08 IL IL26916619A patent/IL269166A/en unknown
-
2021
- 2021-01-20 US US17/153,212 patent/US20210230237A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014141984A (ru) | Способы и композиции для лечения воспаления | |
| JP2015518467A5 (ru) | ||
| EP3664823B1 (en) | Composition for use in preventing or treating an enterococcal blood stream infection | |
| Ouyang et al. | Multifunctional hydrogels based on chitosan, hyaluronic acid and other biological macromolecules for the treatment of inflammatory bowel disease: A review | |
| Baláž et al. | State-of-the-art of eggshell waste in materials science: recent advances in catalysis, pharmaceutical applications, and mechanochemistry | |
| Peng et al. | An intestinal Trojan horse for gene delivery | |
| JP2008546808A5 (ru) | ||
| RU2012153218A (ru) | Пептиды, проникающие в клетки, и их применения | |
| AU2020200008B2 (en) | Polymeric bile acid nanocompositions targeting the pancreas and colon | |
| Binaymotlagh et al. | Peptide-based hydrogels: New materials for biosensing and biomedical applications | |
| RU2018142917A (ru) | Способы и композиции для лечения рассеянного склероза и связанных с ним заболеваний | |
| CN112203669A (zh) | 微生物组相关的免疫疗法 | |
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| AU2018313765A1 (en) | Compositions and methods for decolonizing antibotic-resistant bacteria in the gut | |
| JP2020516621A (ja) | 生体直交型組成物 | |
| RU2016106339A (ru) | Анти-неr2 антитело и его конъюгат | |
| RU2016126425A (ru) | Пептиды, связывающие cd44 | |
| US8895062B2 (en) | Surface-layer protein coated microspheres and uses thereof | |
| CN101780281A (zh) | N-精氨酸壳聚糖作为透皮吸收促进剂的应用 | |
| Lee et al. | Oral administration of microbiome-friendly graphene quantum dots as therapy for colitis | |
| JP6924151B2 (ja) | 免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法 | |
| WO2016011878A1 (zh) | 一种抑制肿瘤转移和治疗白血病的多肽和多肽复合物、其制备方法及其应用 | |
| TW201008946A (en) | Camptothecin polymer derivative and uses of the same | |
| KR101579879B1 (ko) | ｓｉＲＮＡ 전달을 위한 히알루론산-콜레스테롤 나노파티클 및 이를 포함하는 조성물 | |
| CN114748604A (zh) | 一种用于骨髓损伤和/或抑制的复合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant |